Navigation Links
Hope for patients with COPD
Date:8/15/2008

For the first time, a drug therapy appears to reduce lung function loss in patients with moderate to severe chronic obstructive pulmonary disease (COPD), according to the results of a randomized, double-blind, placebo-controlled trial in 42 countries.

The Toward a Revolution in COPD Health (TORCH) study investigated the effects of combined salmeterol, a -agonist, and fluticasone propiniate, an inhaled cortical steroid, either alone or in combination, on mortality, exacerbations, health-related quality of life and rate of decline in lung function as measure by forced expiratory volume in one second (FEV1) in patients with COPD.

The results are published in the second issue for August of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

"Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline on FEV1 in patients with moderate to severe COPD, thus slowing disease progression," wrote Bartolome R. Celli, M.D., lead author of the study and professor at Tufts University School of Medicine. "To date, smoking cessation is the only intervention that has conclusively been shown to alter the rate of decline in FEV1," remarked Dr. Celli. This is the first demonstration of an effective pharmacothrerapy in COPD.

The TORCH study randomized more than 6,000 patients with moderate to severe COPD from 42 countries to receive either salmeterol (SAL; 50 g), fluticasone propionate (FP; 500 g), the two in combination (SFC; 50/500g), or placebo. After baseline FEV1 was recorded, patients were re-evaluated every 24 weeks to determine the rate of decline in FEV1.

"The rate of decline in FEV1 was slowest in patients on SFC and fastest in those randomized to the placebo arm," wrote Dr. Celli. "From week 24 onward, the adjusted rate of decline in FEV1 was 39ml/year for SFC, 42 ml/year for both SAL and FP and 55 ml/year for placebo."

Although the study was not formally powered to detect differences in rate of decline of FEV1, the results were highly significant (p<0.001.) The rate of decline in treatment groups was similar across a number of variables, including sex, age, ethnicity and body mass index. Furthermore, the slower rate of decline in FEV1 appeared to be associated with a lower risk of exacerbation.

"Although treatment did not abolish the accelerated decline in lung function [that occurs with COPD], it did ameliorate it substantially," wrote Dr. Celli, while noting that "the mechanism responsible for the effect on rate of decline is not clear, as all treatments have potentially significant nonbronchodilator effects." Clarifying those mechanisms is the goal of the next phase of the research, with the comparison between a long-acting bronchodilator drug and placebo with respect to FEV1 decline.

In the meantime, "the TORCH study brings some clarity to the treatment picture and provides some hopeful signs for patients with COPD," wrote Samy Suissa, Ph.D., of McGill University, in the accompanying editorial. "This study also demonstrates that no treatment [placebo] is not an option for patients with moderate to severe COPD."


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Prototype test for predicting clinical outcome for melanoma patients
2. Older Patients With Cancer at Heightened Suicide Risk
3. Turbulence Predicts Death Risk for Heart Failure Patients
4. Why dopamine freezes parkinson patients and drives drug addicts
5. Researchers to begin study aimed at helping Latino HIV patients
6. Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients
7. Consumers, Nurses, Seniors Tell Governor: Dont Break Your Promise to Protect Innocent Patients from Health Insurance Cancellations, Dont Weaken Existing Law
8. Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads
9. Bariatric Advantage Announces New Higher-Potency Iron Supplement for Weight Loss Surgery Patients
10. Lap-Band "Tell-All" Warns of Patients Becoming Lap-Band "Orphans"
11. New implant device remotely monitors heart failure patients at Northwestern Memorial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... Hernandez Insurance Agencies, a ... throughout the greater DC region, is inaugurating a “New Leash On Life” charity ... and training them to be companions for veterans in need. , The Semper ...
(Date:8/18/2017)... Humble, TX (PRWEB) , ... August 18, 2017 ... ... insurance management and financial planning firm that serves residential and commercial clients in ... a charity drive to raise community support for the fight against cancer. , ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the ... efforts with its product now available through Jet.com. , After 25 years of ... powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether ...
(Date:8/18/2017)... ... , ... “Three Narrow Roads”: a vivid and provocative look into the narrow ... Burnett King Sr., is currently the pastor-teacher-visionary at Simply the WORD Church, a global ... a track-and-field program geared towards youth. , King shares, “When I take time to ...
(Date:8/18/2017)... ... ... “Prompted By Love”: a love story thrown into doubt by untimely news. “Prompted ... Nettles has devoted her life to ministry since the age of 12 when she ... however, not fulfilled until 2014 when "The Color of Roses" was published. After ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
(Date:8/7/2017)... Insightin Health, provider of data-driven decision-making ... announced the selection of Michael Wood ... as of February 2017. In this role, Wood will ... our clients. Wood brings with him more than ... analytics within the healthcare industry. Wood formerly served ...
(Date:8/7/2017)... Aug. 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Saban as president, effective Aug. 7, 2017. ... decided to pursue other interests and will serve as president ... Paul has served us in multiple leadership roles since he ... Jun. 2015 and has provided decisive, strategic leadership which continues ...
Breaking Medicine Technology: